Liensinine significantly ameliorated HFD-triggered hepatic oxidative stress and dyslipidemia by mediating Nrf2/AMPK signaling, and dimethyl fumarate similarly mitigated NAFLD progression by mediating Nrf2, SREBP-1c, and nuclear factor-κB (NF-κB) signaling [14,15]. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatotic liver disease.